newsfilter
← Latest News
Business Wire·

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus